查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
肝纖維化治療市場：按治療類型、按疾病狀態、按分銷渠道、按地區 - 規模、份額、前景、機會分析，2022-2030
市場調查報告書
商品編碼
1110242

肝纖維化治療市場：按治療類型、按疾病狀態、按分銷渠道、按地區 - 規模、份額、前景、機會分析，2022-2030

Liver Fibrosis Treatment Market, by Treatment Type, by Condition, by Distribution Channel, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030
出版日期: | 出版商: Coherent Market Insights | 英文 168 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

肝纖維化，即膠原蛋白等細胞外基質蛋白的過度積累，發生在大多數類型的慢性肝病中。晚期肝纖維化導致肝硬化、肝功能衰竭和門靜脈高壓症，通常需要肝移植。肝纖維化的特徵是肝臟反復或持續性損傷，導致肝臟瘢痕組織數量異常。纖維化沒有主觀症狀，但隨著瘢痕形成的進展，肝硬化發展，症狀進一步進展。為了確定慢性肝病的嚴重程度，醫療保健從業者將進行血液檢查、影像學檢查，並在必要時進行肝活檢。對於肝纖維化的可能治療方法，醫療專業人員通常專注於治療原因以阻止或減緩肝臟進一步瘢痕形成，從而改善病情。肝纖維化的治療包括使用抗病毒藥物、去除/溶解膽管阻塞、改變生活方式（例如減少酒精攝入）、管理肥胖/超重以及非酒精性脂肪肝患者的血糖水平。脂質水平。

市場動態

在預測期內，隨著高脂飲食人口的增加，非酒精性脂肪性肝炎 (NASH) 的主要患病率預計會增加。隨著主要參與者專注於開發這些疾病的治療方法，肥胖和糖尿病流行、肝纖維化和 NASH 的增加預計將推動市場增長。例如，2022 年 4 月，根據美國國家生物技術信息中心的數據，過去十年美國 NASH 的患病率顯著增加。這可能不僅與提高對該疾病的認識有關，還與增加的風險因素有關。 2021年NASH病例的性別分佈為女性54.1%，男性45.9%。專家估計，大約 24% 的美國成年人患有非酒精性脂肪肝 (NAFLD)，大約 1.5% 至 6.5% 患有 NASH。非酒精性脂肪性肝病 (NAFLD) 會影響 20% 至 30% 的從單純脂肪進展為非酒精性脂肪性肝炎 (NASH) 的人。另外 20% 至 30% 進展為更晚期的非酒精性脂肪性肝炎 (NASH) 纖維化，其最後階段是非酒精性脂肪性肝炎 (NASH) 肝硬化。

本研究的主要特點

  • 本報告對全球肝纖維化治療市場進行了深入分析，揭示了以 2021 年為基準年的預測期內（2022-2030 年）的市場規模（十億美元）和復合年增長率 (CAGR) . %) 提供。
  • 解釋不同細分市場的潛在收入機會，並描述該市場具有吸引力的投資建議矩陣。
  • 該研究還提供了有關市場驅動因素、抑制因素、機會、新產品發布或批准、市場趨勢、區域前景以及主要參與者採用的競爭策略的重要見解。
  • 根據公司亮點、產品組合、關鍵亮點、財務業績和戰略等參數，對全球肝纖維化治療市場的主要參與者進行概況介紹。
  • 本研究涵蓋的主要公司包括 Gilead Sciences, Inc.、Merck & Co., Inc.、Bristol-Myers Squibb、Johnson and Johnson、Novartis AG、Vertex Pharmaceuticals Incorporated、Pfizer Inc.、FibroGen, Inc.。 , 和 Pharmaxis 有限公司
  • 本報告中的見解將使營銷人員和企業高管能夠就未來的產品發布、類型升級、市場擴張和營銷策略做出明智的決策。獎品
  • 全球肝纖維化治療市場報告迎合了該行業的各種利益相關者，包括投資者和供應商、產品製造商、分銷商、新進入者和財務分析師。
  • 通過已用於分析全球肝纖維化治療市場的各種戰略矩陣，利益相關者可以促進決策。

內容

第 1 章目的和先決條件

  • 調查目的
  • 先決條件
  • 縮寫說明

第 2 章市場展望

  • 舉報內容
    • 市場定義和範圍
  • 執行摘要
    • 市場快照：按治療類型
    • 市場快照：按疾病狀態
    • 市場快照：按銷售渠道
    • 市場概況：按地區劃分
  • 連貫的機會圖 (COM)

第 3 章市場動態、監管和趨勢分析

  • 市場動態
    • 驅動程序
    • 約束因素
    • 市場機會
  • 影響分析
  • 市場趨勢
  • 近期趨勢
  • 收購和合作方案
  • 技術概述
  • 監管場景
  • 藥物管線分析
  • 價格分析
  • PEST 分析

第 4 章全球肝纖維化藥物市場 - 冠狀病毒 (COVID-19) 大流行的影響

  • 整體影響
  • 政府舉措
  • COVID-19 對市場的影響

第 5 章全球肝纖維化藥物市場，按治療類型，2017-2030 年

  • 過氧化物□體增殖物激活受體 (PPAR)-α 激動劑
  • ACE抑製劑
  • 益肝藥
  • 其他

第 6 章按疾病狀態分列的肝纖維化藥物全球市場，2017-2030 年

  • 慢性肝病
  • 丙型肝炎
  • 非酒精性脂肪性肝炎

第 7 章按分銷渠道分列的肝纖維化藥物全球市場：2017-2030

  • 醫院
  • 專科診所
  • 其他

第 8 章全球肝纖維化藥物市場：按地區分列，2017-2030

  • 北美
  • 美國
  • 加拿大
  • 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
  • 其他拉丁美洲地區
  • 歐洲
  • 英國
  • 德國
  • 意大利
  • 法國
  • 西班牙
  • 俄羅斯
  • 其他歐洲
  • 亞太地區
  • 中國
  • 印度
  • 日本
  • 東盟
  • 澳大利亞
  • 韓國
  • 其他亞太地區
  • 中東
  • 海合會
  • 以色列
  • 其他中東地區
  • 非洲
  • 北非
  • 中非
  • 南非

第 9 章競爭格局

  • 熱圖分析
  • 市場份額分析
  • 公司簡介
    • Gilead Sciences, Inc.
    • Merck & Co., Inc.
    • Bristol-Myers Squibb
    • Johnson and Johnson
    • Novartis AG
    • Vertex Pharmaceuticals Incorporated
    • Pfizer Inc.
    • FibroGen, Inc.
    • Pharmaxis Limited

第10章 章節

  • 參考文獻
  • 調查手法介紹
簡介目錄
Product Code: CMI2320

Liver fibrosis is the excessive accumulation of extracellular matrix proteins including collagen that occurs in most types of chronic liver diseases. Advanced liver fibrosis results in cirrhosis, liver failure, and portal hypertension and often requires liver transplantation. Liver fibrosis is characterized by repeated or continuous damage to liver resulting in an abnormally large amount of scar tissue in the liver. Fibrosis does not show any symptoms, however severe scarring results into cirrhosis, which further leads to cause symptoms. To detect the severity of chronic liver disease, healthcare professionals conduct blood and imaging test, followed by liver biopsy, if required. In the possible treatment options for liver fibrosis, healthcare professionals focus on treating the cause, which often stops and slows down further scarring of liver and results in improvement of the condition. The possible treatment options for liver fibrosis include use of antiviral drugs, removal or dissolution of a blockage in the bile ducts, lifestyle changes such as lower consumption of alcohol, control regime for obesity and overweight, and controlling blood sugar & lipid levels in people with nonalcoholic fatty liver.

Market Dynamics

The underlining prevalence cases of Non-alcoholic Steatohepatitis (NASH) are expected to increase over the forecast period with increasing amount of population consuming high fat diet. Increasing obesity and diabetes epidemics, liver fibrosis, and NASH are expected to drive market growth, as key players are focused on developing treatment for these disorders. For instance, in April 2022, according to National Center for Biotechnology Information, the prevalence of NASH has significantly increased in the U.S. in the last decade. This is likely related to the increased prevalence of risk factors as well as increased awareness of the disease. The proportion of patients with NASH by gender was 54.1% female verses 45.9% male in 2021. Experts estimate about 24% of U.S. adults have Non-alcoholic fatty liver disease (NAFLD) and about 1.5% to 6.5% of U.S. adults have NASH. Non-alcoholic fatty liver disease (NAFLD) states as simple fat, which impacts on 20% to 30% of those individuals who progress to nonalcoholic steatohepatitis (NASH). Another 20% to 30% of individual's progress to more advanced Non-alcoholic Steatohepatitis (NASH) fibrosis, and the final stage is Non-alcoholic Steatohepatitis (NASH) cirrhosis.

Key features of the study:

  • This report provides an in-depth analysis of the global liver fibrosis treatment market, and provides market size (US$ Billion) and compound annual growth rate (CAGR%) for the forecast period (2022-2030), considering 2021 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global liver fibrosis treatment market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
  • Key companies covered as a part of this study include Gilead Sciences, Inc., Merck & Co., Inc., Bristol-Myers Squibb, Johnson and Johnson, Novartis AG, Vertex Pharmaceuticals Incorporated, Pfizer Inc., FibroGen, Inc., and Pharmaxis Limited
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • The global liver fibrosis treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global liver fibrosis treatment market

Detailed Segmentation:

  • Global Liver Fibrosis Treatment, By Treatment Type :
    • Peroxisome Proliferator-activated Receptors (PPAR)-alpha agonist
    • ACE Inhibitors
    • Hepatotropic Drug
    • Others
  • Global Liver Fibrosis Treatment, By Condition:
    • Chronic Liver Diseases
    • Hepatitis C
    • Nonalcoholic Steatohepatitis
  • Global Liver Fibrosis Treatment, By Distribution Channel:
    • Hospitals
    • Specialty Clinics
    • Others
  • Global Liver Fibrosis Treatment, By Region:
    • North America
      • By Country
    • U.S.
    • Canada
    • Latin America
      • By Country
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
    • Europe
      • By Country
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Russia
    • Rest of Europe
    • Asia Pacific
      • By Country
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
    • Middle East
      • By Country
    • GCC
    • Israel
    • Rest of Middle East
    • Africa
      • By Region/Country
    • South Africa
    • Central Africa
    • North Africa
  • Company Profiles
    • Gilead Sciences, Inc.*
      • Company Highlights
      • Products Portfolio
      • Key Highlights
      • Financial Performance
      • Strategies
    • Merck & Co., Inc.
    • Bristol-Myers Squibb
    • Johnson and Johnson
    • Novartis AG
    • Vertex Pharmaceuticals Incorporated
    • Pfizer Inc.
    • FibroGen, Inc.
    • Pharmaxis Limited

"*" marked represents similar segmentation in other categories in the respective section.

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snapshot, By Treatment Type
    • Market Snapshot, By Condition
    • Market Snapshot, By Distribution Channel
    • Market Snapshot, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Drivers
    • Restraints
    • Market Opportunities
  • Impact Analysis
  • Market Trends
  • Recent Developments
  • Acquisitions and Partnerships Scenario
  • Technology Overview
  • Regulatory Scenario
  • Drug Pipeline Analysis
  • Pricing Analysis
  • PEST Analysis

4. Global Liver Fibrosis Treatment Market- Impact of Coronavirus (Covid-19) Pandemic

  • Overall Impact
  • Government Initiatives
  • COVID-19 Impact on the market

5. Global Liver Fibrosis Treatment Market, By Treatment Type, 2017 - 2030, (US$ Billion)

  • Overview
    • Market Share Analysis, 2022 and 2030 (%)
    • Y-o-Y Growth Analysis, 2017 - 2030
    • Segment Trends
  • Peroxisome Proliferator-activated Receptors (PPAR)-alpha agonist
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Billion)
  • ACE Inhibitors
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Billion)
  • Hepatotropic Drug
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Billion)
  • Others
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Billion)

6. Global Liver Fibrosis Treatment Market, By Condition, 2017 - 2030, (US$ Billion)

  • Overview
    • Market Share Analysis, 2022 and 2030 (%)
    • Y-o-Y Growth Analysis, 2017 - 2030
    • Segment Trends
  • Chronic Liver Disease
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Billion)
  • Hepatitis C
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Billion)
  • Nonalcoholic Steatohepatitis
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Billion)

7. Global Liver Fibrosis Treatment Market, By Distribution Channel, 2017 - 2030, (US$ Billion)

  • Overview
    • Market Share Analysis, 2022 and 2030 (%)
    • Y-o-Y Growth Analysis, 2017 - 2030
    • Segment Trends
  • Hospitals
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Billion)
  • Specialty Clinics
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Billion)
  • Others
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Billion)

8. Global Liver Fibrosis Treatment Market, By Region, 2017 - 2030, (US$ Billion)

  • Introduction
    • Market Share Analysis, By Region, 2022 and 2030 (%)
    • Y-o-Y Growth Analysis, For Regions, 2017-2030
    • Regional Trends
  • North America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2017 - 2030, (US$ Billion)
    • Market Size and Forecast, and Y-o-Y Growth, By Condition, 2017 - 2030, (US$ Billion)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Billion)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Billion)
  • U.S.
  • Canada
  • Latin America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2017 - 2030, (US$ Billion)
    • Market Size and Forecast, and Y-o-Y Growth, By Condition, 2017 - 2030, (US$ Billion)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Billion)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Billion)
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
  • Europe
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2017 - 2030, (US$ Billion)
    • Market Size and Forecast, and Y-o-Y Growth, By Condition, 2017 - 2030, (US$ Billion)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Billion)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Billion)
  • U.K.
  • Germany
  • Italy
  • France
  • Spain
  • Russia
  • Rest of Europe
  • Asia Pacific
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2017 - 2030, (US$ Billion)
    • Market Size and Forecast, and Y-o-Y Growth, By Condition, 2017 - 2030, (US$ Billion)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Billion)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Billion)
  • China
  • India
  • Japan
  • ASEAN
  • Australia
  • South Korea
  • Rest of Asia Pacific
  • Middle East
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2017 - 2030, (US$ Billion)
    • Market Size and Forecast, and Y-o-Y Growth, By Condition, 2017 - 2030, (US$ Billion)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Billion)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Billion)
  • GCC
  • Israel
  • Rest of Middle East
  • Africa
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2017 - 2030, (US$ Billion)
    • Market Size and Forecast, and Y-o-Y Growth, By Condition, 2017 - 2030, (US$ Billion)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Billion)
    • Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2017 - 2030, (US$ Billion)
  • North Africa
  • Central Africa
  • South Africa

9. Competitive Landscape

  • Heat Map Analysis
  • Market Share Analysis
  • Company Profiles
    • Gilead Sciences, Inc.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
    • Merck & Co., Inc.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
    • Bristol-Myers Squibb
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
    • Johnson and Johnson
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
    • Novartis AG
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
    • Vertex Pharmaceuticals Incorporated
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
    • Pfizer Inc.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
    • FibroGen, Inc.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
    • Pharmaxis Limited
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies

10. Section

  • References
  • Research Methodology
  • About Us and Sales Contact